Reapplix A/S

Reapplix APS has postponed indefinitely plans to roll out its proprietary biological wound-healing patch in Europe for treating patients with diabetic foot ulcers due to uncertainty over product reimb

Wound-therapy specialist Reapplix APS says it's moving forward with US commercial activities to support its LeucoPatch wound-healing platform now that the results of a randomized trial assessing

Reapplix APS has raised €2.7m ($3.04m) in new capital to support activities that will put the Danish firm on the path to getting that all-important reimbursement for its advanced wound-care product,

Projected to reach $6 billion in worldwide revenues by year’s end, the business of advanced wound care has transformed from a sleepy commoditized marketplace to a robust high-growth, hi-tech arena whe